Here’s What You Need to Know About COVID’s XBB.1.5 ‘Kraken’ Variant

Argentina Noticias Noticias

Here’s What You Need to Know About COVID’s XBB.1.5 ‘Kraken’ Variant
Argentina Últimas Noticias,Argentina Titulares
  • 📰 ClevelandScene
  • ⏱ Reading Time:
  • 64 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 29%
  • Publisher: 55%

The omicron offshoot’s ability to easily infect cells may be helping it spread rapidly in places

The omicron variant’s family tree has grown substantially over the last year. The brood now encompasses a subvariant soup with alphanumeric names such as BA.2, BA.5 and BF.7. The U.S. Centers for Disease Control and Prevention estimates that two versions — BQ.1 and BQ.1.1 — caused just over half of new infections in the United States during the week ending January 7.

Science News spoke with infectious diseases specialist Peter Chin-Hong of the University of California, San Francisco about the latest coronavirus variant to make headlines. The conversation has been edited for length and clarity.Chin-Hong: There are lots of variants that get produced all the time. It’s a normal thing for the virus as the virus makes more copies of itself. It’s not exactly precise or accurate, so it makes errors, [which are the variants].

You can have somebody who got infected two or three times plus they got vaccinated and boosted. That’s going to be somebody who’s going to be really, really well protected against getting seriously ill. Maybe they might get a cold. Maybe they wouldn’t even know they had an infection versus somebody who didn’t get vaccinated and never got exposed and they’re older. It might as well be March of 2020 for them.

[Drugs such as] Paxlovid and remdesivir work independent of the spike protein [the part of the virus targeted by vaccines but where many of the defense-evading mutations are ]. So it doesn’t matter what invisibility cloak the variant has. They’re going to work because they work on shutting down the virus factory, which is one of the early steps, before the spike protein gets made.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

ClevelandScene /  🏆 383. in US

Argentina Últimas Noticias, Argentina Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Omicron sub-variant XBB.1.5 accounts for 61.3% of U.S. COVID cases - CDCOmicron sub-variant XBB.1.5 accounts for 61.3% of U.S. COVID cases - CDCThe Omicron subvariant XBB.1.5 has likely become the dominant variant in the United States, accounting for 61.3% of COVID cases in the week ended Jan. 28, data from the U.S. Centers for Disease Control and Prevention showed on Friday.
Leer más »

COVID, flu and RSV hospitalizations keep falling in ColoradoCOVID, flu and RSV hospitalizations keep falling in ColoradoPublic health officials are watching the variants, but right now there’s no sign that XBB.1.5 will be able to reverse the declining trajectory in Colorado.
Leer más »

FDA pulls authorization for AstraZeneca’s Covid antibody drug EvusheldFDA pulls authorization for AstraZeneca’s Covid antibody drug EvusheldThe drug, meant to prevent Covid in people with weakened immune systems, does not work against the predominant omicron subvariant XBB.1.5.
Leer más »

Biology: New immune-evading COVID variants could fuel surgeBiology: New immune-evading COVID variants could fuel surgeNew Omnicron strain XBB.1.5 shows COVID virus is still evolving. Understanding why virus has changed, and what it means for the future can be helpful.
Leer más »

Omicron sub-variant XBB.1.5 accounts for 61.3% of U.S. COVID cases - CDCOmicron sub-variant XBB.1.5 accounts for 61.3% of U.S. COVID cases - CDCThe Omicron subvariant XBB.1.5 has likely become the dominant variant in the United States, accounting for 61.3% of COVID cases in the week ended Jan. 28, data from the U.S. Centers for Disease Control and Prevention showed on Friday.
Leer más »

FDA pulls authorization for AstraZeneca’s Covid antibody drug EvusheldFDA pulls authorization for AstraZeneca’s Covid antibody drug EvusheldThe drug, meant to prevent Covid in people with weakened immune systems, does not work against the predominant omicron subvariant XBB.1.5.
Leer más »



Render Time: 2025-04-08 10:30:12